Asset Details
Do you wish to reserve the book?
K2P18.1 translates T cell receptor signals into thymic regulatory T cell development
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
K2P18.1 translates T cell receptor signals into thymic regulatory T cell development
Do you wish to request the book?
K2P18.1 translates T cell receptor signals into thymic regulatory T cell development
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
K2P18.1 translates T cell receptor signals into thymic regulatory T cell development
2022
Overview
It remains largely unclear how thymocytes translate relative differences in T cell receptor (TCR) signal strength into distinct developmental programs that drive the cell fate decisions towards conventional (Tconv) or regulatory T cells (Treg). Following TCR activation, intracellular calcium (Ca
2+
) is the most important second messenger, for which the potassium channel K
2P
18.1 is a relevant regulator. Here, we identify K
2P
18.1 as a central translator of the TCR signal into the thymus-derived Treg (tTreg) selection process. TCR signal was coupled to NF-κB-mediated K
2P
18.1 upregulation in tTreg progenitors. K
2P
18.1 provided the driving force for sustained Ca
2+
influx that facilitated NF-κB- and NFAT-dependent expression of FoxP3, the master transcription factor for Treg development and function. Loss of K
2P
18.1 ion-current function induced a mild lymphoproliferative phenotype in mice, with reduced Treg numbers that led to aggravated experimental autoimmune encephalomyelitis, while a gain-of-function mutation in K
2P
18.1 resulted in increased Treg numbers in mice. Our findings in human thymus, recent thymic emigrants and multiple sclerosis patients with a dominant-negative missense K
2P
18.1 variant that is associated with poor clinical outcomes indicate that K
2P
18.1 also plays a role in human Treg development. Pharmacological modulation of K
2P
18.1 specifically modulated Treg numbers in vitro and in vivo. Finally, we identified nitroxoline as a K
2P
18.1 activator that led to rapid and reversible Treg increase in patients with urinary tract infections. Conclusively, our findings reveal how K
2P
18.1 translates TCR signals into thymic T cell fate decisions and Treg development, and provide a basis for the therapeutic utilization of Treg in several human disorders.
